Provided by Tiger Fintech (Singapore) Pte. Ltd.

Athira Pharma, Inc.

0.3353
+0.01735.44%
Post-market: 0.33960.0043+1.28%19:11 EDT
Volume:118.85K
Turnover:39.46K
Market Cap:13.09M
PE:-0.13
High:0.3398
Open:0.3180
Low:0.3170
Close:0.3180
Loading ...

Company Profile

Company Name:
Athira Pharma, Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
26
Office Location:
18706 North Creek Parkway,Suite 104,Bothell,Washington,United States
Zip Code:
98011
Fax:
- -
Introduction:
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Directors

Name
Position
Leen Kawas
President, Chief Executive Officer and Director
Tadataka Yamada
Chairman of the Board
James A. Johnson
Director
John M. Fluke, Jr.
Director
Joseph Edelman
Director

Shareholders

Name
Position
Leen Kawas
President, Chief Executive Officer and Director
Mark Litton
Chief Operating Officer
Glenna Mileson
Chief Financial Officer and Corporate Secretary
Hans Moebius
Chief Medical Officer
Kevin Church
Vice President of Discovery